Vonoprazan-based triple tx feasible for H. pylori

Vonoprazan-based triple tx feasible for <i>H. pylori</i>

(HealthDay)—The potassium-competitive acid blocker vonoprazan-based triple therapy seems safe and effective compared with conventional proton pump inhibitor (PPI)-based triple therapy as first-line treatment against Helicobacter pylori, according to a study published online Aug. 17 in the Journal of Digestive Diseases.

Satoki Shichijo, M.D., Ph.D., from the University of Tokyo, and colleagues performed a multicenter study involving 2,715 patients who received first-line H. pylori eradication therapy. Vonoprazan-based triple therapy was compared with conventional PPI-based triple therapy.

The researchers found that eradication rates were 87.2 and 72.4 percent for vonoprazan-based and conventional PPI-based therapy, respectively (P < 0.01). There were 10 cases of diarrhea, six of nausea/vomiting, and five of rash in the vonoprazan-based therapy group; these rates were not higher than those in the conventional PPI-based group.

"Vonoprazan-based is feasible; it showed a higher eradication rate than conventional PPIs as a first-line regimen," the authors write.

Explore further

Recommendations updated for H. pylori treatment in adults

More information: Abstract
Full Text (subscription or payment may be required)

Copyright © 2016 HealthDay. All rights reserved.

Citation: Vonoprazan-based triple tx feasible for H. pylori (2016, August 25) retrieved 6 December 2019 from https://medicalxpress.com/news/2016-08-vonoprazan-based-triple-tx-feasible-pylori.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments